文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌寡复发淋巴结的挽救性扩大野与累及野放疗对比

Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-28

本研究纳入62例根治性前列腺切除或放疗后PSA升高、18F-氟胆碱PET/CT显示仅阳性淋巴结的前列腺癌患者,比较挽救性累及野放疗(s-IFRT,35例)与扩大野放疗(s-EFRT,27例)。中位随访41.8个月,两组≥2级急性和晚期胃肠及泌尿生殖毒性无差异;s-IFRT组3年失败率为55.3%(95%CI 37.0-70.3%),s-EFRT组为88.3%(95%CI 66.9-96.1%)(p=0.0094)。多因素分析中,间隔>5年与更好结局显著相关(HR=0.33,95%CI 0.13-0.86,p=0.023)。

要点

  • s-IFRT组3年失败率55.3%(95%CI 37.0-70.3%),s-EFRT组88.3%(95%CI 66.9-96.1%),p=0.0094。
  • 两组≥2级急性或晚期胃肠及泌尿生殖毒性无差异。
  • 多因素分析中,间隔>5年与更好结局显著相关(HR=0.33,95%CI 0.13-0.86,p=0.023)。

核心结论

  • 作者认为,18F-氟胆碱PET阳性淋巴结靶向的s-EFRT可行、毒性低且无失败时间(TTF)更长,提示FCH PET诊断的寡复发淋巴结病变不太可能。

研究设计与样本

  • 单中心回顾性研究,纳入2009年至2017年间在一家三级癌症中心接受挽救性放疗的FCH PET/CT显示寡复发淋巴结的前列腺癌患者。
  • 共62例仅阳性淋巴结患者,其中35例接受s-IFRT,27例接受s-EFRT,比较两组毒性和失败时间(TTF)。

主要发现

  • 中位随访41.8个月(范围5.9-108.1个月),两组≥2级急性或晚期胃肠及泌尿生殖毒性无差异。
  • s-IFRT组3年失败率为55.3%(95%CI 37.0-70.3%),s-EFRT组为88.3%(95%CI 66.9-96.1%),p=0.0094。
  • 多因素分析中,间隔>5年与更好结局显著相关(HR=0.33,95%CI 0.13-0.86,p=0.023)。
  • 调整同期雄激素剥夺治疗后,s-EFRT仍有更好结局的强烈趋势(HR=0.38,95%CI 0.12-1.27,p=0.116)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The concept of metastasis-directed therapy for nodal oligorecurrences with stereotactic body radiotherapy is increasingly accepted. Hence, the comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with 18F-fluorocholine (FCH) PET/CT+ nodal oligorecurrences from prostate cancer is worthy of investigation. METHODS: Patients with oligorecurrent nodes on FCH PET/CT treated with salvage radiotherapy between 2009 and 2017 in a single tertiary cancer centre were selected for this study. Patients treated with s-IFRT were compared with those treated with s-EFRT. Toxicities and times to failure (TTF) were compared between the two groups. RESULTS: The study included 62 patients with positive lymph nodes only who underwent FCH PET/CT for a rising PSA level after radical prostatectomy or radiotherapy. Of these patients, 35 had s-IFRT and 27 had s-EFRT. After a median follow-up of 41.8 months (range 5.9-108.1 months), no differences were observed in acute or late gastrointestinal and genitourinary toxicities of grade 2 or more between the two groups. The 3-year failure rates were 55.3% (95% CI 37.0-70.3%) in the s-IFRT group and 88.3% (95% CI 66.9-96.1%) in the s-EFRT group (p = 0.0094). In multivariate analysis of TTF, an interval of >5 years was significantly correlated with better outcomes (HR = 0.33, 95% CI 0.13-0.86, p = 0.023). There was a strong trend toward better outcomes with s-EFRT even after adjusting for concomitant androgen-deprivation therapy (HR = 0.38, 95% CI 0.12-1.27, p = 0.116). CONCLUSION: FCH PET-positive node-targeted s-EFRT is feasible with low rates of toxicity and longer TTF, suggesting that oligorecurrent nodal disease diagnosed on FCH PET is unlikely.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lépinoy A, Silva YE, Martin E, et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 30267117. doi:10.1007/s00259-018-4159-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。